Fullgoal CSI Hugangshen Innovative Drugs Industry ETF(159748.SZ)

Last Updated 00:00:00
longbridge loading
Company Encyclopedia
View More
name
Fullgoal CSI Hugangshen Innovative Drugs Industry ETF
159748.SZ
News
View More

WuXi AppTec Receives MSCI AAA ESG Rating and CDP 'A' Scores for Climate and Water

WuXi AppTec Co. Ltd. has received the MSCI AAA ESG rating and has been recognized on the CDP 'A List' for its leadership in climate change and water security. The company has achieved the highest ratings in both categories, reflecting its commitment to sustainability. WuXi AppTec has been included in the Dow Jones Sustainability Index and the FTSE4Good Index, and has received a Gold Medal from EcoVadis for sustainability. Additionally, its emissions reduction targets have been validated by the Science Based Targets initiative.

Reuters·
SH
603259
-2.77%
HK
02359
-3.64%
Reuters·
SH
603259
-2.77%
HK
02359
-3.64%

JPM26: Bi- and multispecific modalities power Wuxi Biologics growth

Wuxi Biologics showcased its integrated platform for biologics at the JP Morgan Healthcare Conference, emphasizing its end-to-end capabilities in research, development, and manufacturing. CEO Chris Chen highlighted their success with over 600 INDs and a 100% regulatory inspection success rate. The company focuses on bi- and multispecifics, ADCs, and mAbs, which contribute 20% of revenue. Wuxi is expanding its manufacturing capacity in the US and Asia, including a new facility in Qatar. Chen noted the adoption of AI technologies to enhance operations, predicting significant revenue growth in 2026 and beyond.

Pharmaceutical Technology·
US
WXXWY
+1.60%
HK
02269
-5.83%
Pharmaceutical Technology·
US
WXXWY
+1.60%
HK
02269
-5.83%

23:00 ET JPM Highlights | WuXi Biologics CEO Dr. Chris Chen: Scaled CRDMO Platform Delivering Sustainable High Growth

Dr. Chris Chen, CEO of WuXi Biologics, presented at the J.P. Morgan Healthcare Conference, highlighting the company's growth and achievements for 2025. WuXi Biologics plans to complete 945 integrated projects, with a significant focus on bispecific/multispecific antibodies and ADCs, which are driving revenue growth. The company has secured record-breaking deals and is expanding its global manufacturing capabilities. WuXi Biologics aims to enhance its CRDMO model to support biopharmaceutical innovators, showcasing strong client trust and a robust project pipeline.

prnewswire·
US
WXXWY
+1.60%
HK
02269
-5.83%
prnewswire·
US
WXXWY
+1.60%
HK
02269
-5.83%

WuXi AppTec Highlights Global CRDMO Growth and Innovation Platform in Latest Presentation

WuXi AppTec Co. Ltd. has presented its business strategy and performance in the CRDMO sector, highlighting a robust pipeline with 2,889 preclinical and Phase I molecules, 374 in Phase II, and 87 in Phase III as of Q3 2025. The company reported an adjusted non-IFRS net profit of RMB 15.0 billion in 2025, with a net profit margin of 32.9%. WuXi AppTec is expanding its global presence in regions including Boston, New Jersey, and Munich.

Reuters·
SH
603259
-2.77%
HK
02359
-3.64%
Reuters·
SH
603259
-2.77%
HK
02359
-3.64%

Akeso Reports Cadonilimab Outperforms PD-1 Inhibitors in First-Line PD-L1-Low Gastric Cancer Study

Akeso Inc. reported that cadonilimab plus chemotherapy outperformed PD-1 inhibitors in a study for first-line treatment of advanced gastric cancer with PD-L1 CPS

Reuters·
HK
09926
-3.06%
Reuters·
HK
09926
-3.06%
© 2026 Longbridge｜Disclaimer